Effect of Convalescent Plasma on Mortality among Hospitalized Patients with COVID-19 Initial Three-Month Experience.

The authors evaluated 7 and 30-day mortality in 35,322 hospitalized adult patients transfused with COVID-19 convalescent plasma as part of the U.S. Expanded Access Program for those with laboratory-confirmed infection and severe or life-threatening COVID-19. The authors found that earlier use of convalescent plasma and use of convalescent plasma with higher antibody levels were both associated with lower rates of 7 and 30-day mortality.